San Diego—In older patients with newly diagnosed chronic lymphocytic leukemia (CLL), the BTK inhibitor ibrutinib provided a significant advantage for the primary end point of progression-free survival (PFS) compared with the standard of bendamustine plus rituximab.
After a median 38 months of follow-up, the rate of progression or death was 61% lower among patients treated with oral ibrutinib (Imbruvica, Pharmacyclics/Janssen) relative to those treated with bendamustine and rituximab